Adenovirus (AdV) can cause severe pneumonia in non-immunocompromised host, but limited data exist on the distinctive characteristics of AdV pneumonia in nonimmunocompromised patients. We evaluated distinctive clinico-laboratory and radiological characteristics and outcomes of AdV pneumonia (n = 179), compared with non-AdV pneumonia (n = 188) in Korean military personnel between 2012 and 2016. AdV pneumonia patients had a higher rate of consolidation with ground-glass opacity (101/152) in lobar distribution (89/152) on computed tomography (CT) (P < 0.001). Laboratory findings showed a higher incidence of unusual blood profiles such as leukopenia (55/179, P < 0.001) or thrombocytopenia (100/179, P < 0.001). The patients had more systemic symptoms such as myalgia (82/179, P = 0.001) or diarrhea (23/179, P < 0.001), compared with non-AdV pneumonia patients. Bacterial co-infection was identified in 28.5% of AdV pneumonia. Most of the AdV isolates typed (69/72, 95.8%) were AdV-55. Patients with a pneumonia severity index ≥ class III were more commonly observed in AdV pneumonia patients compared with non-AdV pneumonia patients (11.2% vs. 2.1%, P < 0.001), and time to clinical stabilization from admission was longer in the AdV pneumonia patients compared with the non-AdV pneumonia patients (3.8 vs. 2.6 days, P < 0.001). Mechanical ventilation (n = 6) was only required in AdV pneumonia patients, one of whom died due to AdV-55. Our data showed that AdV pneumonia in non-immunocompromised patients had distinct characteristics and most of the isolates typed in our study were AdV-55. It is suggested that AdV-55 is an important pathogen of pneumonia in Korean military personnel.
INTRODUCTION
Adenoviruses (AdV) are non-enveloped, double-stranded DNA viruses that can cause diseases of the respiratory tract, and gastrointestinal and ocular systems (1) . It is well-known that AdV respiratory tract infections are usually mild and self-limiting in a non-immunocompromised host, in contrast with immunocompromised hosts, in whom AdV infection can be fatal (2) (3) (4) . Since the fatal case of AdV pneumonia in a healthy adult was described in the 1960s (5), severe disease caused by AdV has been reported among non-immunocompromised adults, especially in vulnerable populations, such as military recruits and residents of health care facilities (6) (7) (8) (9) . Recent studies have also described fatal cases of severe AdV pneumonia caused by particular serotypes, which provide insight into emerging, highly virulent serotypes, even in non-immunocompromised patients (10) (11) (12) (13) (14) .
In the Armed Forces Capital Hospital, the largest military referral center in Korea, the number of community acquired pneumonia (CAP) patients, admitted with varying severities of disease, has increased annually; among these cases, the AdV isolation rates have been steadily increasing over recent years and fatal cases have been reported since 2012 (15) (16) (17) . Thus, physicians have tried to identify the causative respiratory viral agents at an early stage to produce favorable outcomes, with these efforts, we have recently reported clinical data on the outcome of administration of antiviral agents, and factors predictive of respiratory failure in AdV pneumonia (16, 17) .
However, there is limited data on the distinctive characteristics of AdV pneumonia in non-immunocompromised patients, which could help a physician to determine a diagnostic or treatment strategy during early presentation. Therefore, in the present study, we evaluated the characteristics of AdV-associated vs. non-AdV pneumonia cases among Korean military personnel between 2012 and 2016, and additionally described the characteristics of the AdV pneumonia caused by the serotype of AdV-55 which was most commonly isolated type.
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MATERIALS AND METHODS

Study subjects
We reviewed the medical records of 557 consecutive adult patients who were admitted with acute febrile respiratory illness, between July 2012 and January 2016, to the Armed Forces Capital Hospital, Korea. All patients were serving in the military service and were non-immunocompromised with negative human immunodeficiency virus infection tests. Of these patients, those with upper respiratory tract infection (URI) or bronchitis (n = 17), and those who did not undergo a respiratory virus polymerase chain reaction (PCR) test (n = 173), were excluded. Consequently, 367 patients with CAP were included in the analysis; of these, 179 with AdV pneumonia and 188 with non-AdV pneumonia were identified and included in the analysis (Fig. 1) .
The diagnosis of AdV pneumonia was considered confirmed when the following findings were present: 1) acute lower respiratory symptoms; 2) definite infiltration on radiography or computed tomography (CT); and 3) evidence of AdV infection identified by a respiratory virus PCR test from lower respiratory specimens including sputum or bronchoalveolar lavage fluid. When specimens sampled from the lower respiratory tract were considered inadequate, specimens from the upper respiratory tract, including nasopharyngeal or oropharyngeal swabs, were obtained (16, 17) .
The serotype of AdV-positive specimens was evaluated in some patients. Before June 2014, serotype analysis was performed only in severe cases based on the attending physician's decision (16) . Between December 2014 and March 2015, because the number of CAP patients had increased and more severe patients with unusual blood profiles such as leukopenia or thrombocytopenia were referred to the Armed Forces Capital Hospital (Fig. 2) , serotype analysis was more frequently performed cooperated by the Armed Forces Medical Command (17) . During the same period, serotype analysis was also performed in some outpatients without pneumonia but who had severe symptoms based on the attending physician's decision. The present study included previously published data on patients with AdV pneumonia treated at the Armed Forces Capital Hospital (15) (16) (17) .
Patient management and data collection
Patients who had persistent symptoms, or who deteriorated despite appropriate empirical antibiotics for 2-3 days, and/or who had unusual blood profiles including leukopenia or thrombocytopenia, were suspected of having atypical causative agents and underwent etiological investigations. Etiologies were evaluated in blood, sputum, bronchoalveolar lavage fluids, nasopharyngeal or oropharyngeal secretions, and urine using microbiological culture for bacteria; a multiplex real-time PCR test for bacterial agents including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, and Chlamydia pneumoniae; a multiplex real-time PCR test for respiratory viruses; and a urinary antigen test for S. pneumoniae or Legionella pneumophila. Antiviral therapy with cidofovir was applied in some severe patients (3, 16) . The serotype of human-AdV-positive samples was investigated by sequencing the partial hexon genomic region (16, 17) .
Statistical analysis
Data are shown as means ± standard deviation (SD) for continuous variables and as numbers and percentages for categorical variables. Data were compared using a two-sample t-test for continuous variables, and by χ 2 or Fisher's exact test for categorical variables. Statistical analyses were performed using PASW software (ver. 18.0; SPSS Inc., Chicago, IL, USA) and a two-sided P value < 0.05 was considered to indicate statistical significance.
Ethics statement
The Institutional Review Board of the Armed Forces Medical Command and Armed Forces Capital Hospital approved this study and permitted the review and publication of patient records (AFMC-16-IRB-037). The requirement for informed consent by individual patients was waived given the retrospective nature of the study.
RESULTS
Comparisons of clinical characteristics between AdV and non-AdV pneumonia
We compared clinical characteristics between the AdV and nonAdV pneumonia patients (Table 1) . Most patients were previously healthy males with a mean age of 22 years, and a minority of patients had underlying conditions such as asthma (n = 3), bronchiectasis (n = 3), tuberculosis (n = 2), or congenital cystic malformation (n = 1). All patients presented with clinical symptoms or signs, and AdV pneumonia patients had higher rates of sore throat, myalgia, and diarrhea. Patients with AdV pneumonia were more likely to have clinical instabilities, defined as fever ( ≥ 38.3°C), dyspnea ( ≥ modified Medical Research Council [mMRC] II), tachypnea ( > 30 breaths/min), tachycardia ( > 100 beats/min), oxygen requirement, and inability to eat, compared with patients with non-AdV pneumonia (18) . Patients with pneumonia severity index ≥ class III were more commonly observed in the AdV pneumonia. The time from symptom onset to hospital admission tended to be longer in the AdV pneumonia patient group than in the non-AdV pneumonia patient group; however, there was no significant difference between the 2 groups. 
Comparisons of laboratory findings between AdV and non-AdV pneumonia
We compared the laboratory findings between the AdV and nonAdV pneumonia patients ( Table 2) . The white blood cell (WBC) count and platelet count in AdV pneumonia patients were lower than those of non-AdV pneumonia patients, and leukopenia and thrombocytopenia were more commonly observed in AdV pneumonia patients (all P < 0.001). Pleural fluid analyses were performed in eight AdV pneumonia patients and all had lymphocyte-dominant exudates and elevated adenosine deami- nase levels ( ≥ 40 IU/L), and there was no evidence of mycobacterial infection in all pleural fluid analysis. In total, 13 of the 179 (7.3%) AdV pneumonia patients had co-infections with respiratory viruses other than AdV, such as rhinovirus (n = 10), parainfluenza virus (n = 2), and enterovirus (n = 1). Most of the isolates typed (69/72, 95.8%) were AdV-55. More than two-thirds (121/179, 67.6%) of AdV pneumonia patients had positive AdV PCR sputum specimens. Bacterial agents were more commonly identified (58/148, 39.2%) in the non-AdV pneumonia patients (P = 0.001), of whom one had pneumococcal bacteremia. Interestingly, in the AdV pneumonia patients, co-infection with bacterial agents, such as S. pneumoniae followed by H. influenzae and M. pneumoniae, was not uncommon (47/165, 28.5%).
During the study period, PCR tests of nasopharyngeal or oropharyngeal secretions for respiratory viruses were performed in some outpatients without evidence of pneumonia on chest radiography, but who had severe upper respiratory symptoms; 49 patients were confirmed to have AdV infection. A serotype analysis was also performed and AdV-55 (n = 46, 94.0%) was the most commonly identified serotype, followed by AdV-6 (n = 1, 2%), AdV-5 (n = 1, 2%), and AdV-1 (n = 1, 2%).
Comparisons of initial chest CT findings between AdV and non-AdV pneumonia
Of the study patients, initial chest CT images were available in 292 patients (Table 3) . Notably, approximately 60% of AdV pneumonia patients had consolidation with ground-glass opacity patterns in lobar distribution (Fig. 3) , which represented a higher frequency compared with that in the non-AdV pneumonia patients (both, P < 0.001). The mainly involved lobe in the 2 groups tended to differ; however, lower lobe involvement (left, right, and both lower lobe) was commonly observed in both AdV and non-AdV pneumonia patients.
Comparisons of treatment outcomes between AdV and non-AdV pneumonia
Of the 367 study patients, 324 who had detailed medical records during hospitalization were included in the final outcome analysis (Table 4 ). All 324 patients received empirical antibiotics: a 3rd-generation cephalosporin plus an azalide was the most common treatment (n = 133, 41.1%), followed by respiratory quinolone (n = 75, 23.2%). Cidofovir was administered in 34 AdV pneumonia patients and adjuvant intravenous immunoglobulin (IVIG) was also administered in 14 AdV pneumonia patients. Mechanical ventilation (n = 6) and extracorporeal membrane oxygenation (ECMO) support (n = 1) were needed only in AdV pneumonia patients.
Respiratory failure, defined as partial pressure of arterial oxygen/fraction of inspired oxygen (FiO2) ratio ≤ 300 with or without tachypnea, occurred more commonly in AdV pneumonia patients than in non-AdV pneumonia patients (P = 0.001). Of the 37 AdV pneumonia patients who had respiratory failure, 23 had initial respiratory failure at the time of admission and 14 
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progressed to respiratory failure during hospitalization. Time to overall clinical stabilization from admission was significantly longer in the AdV pneumonia patients than in the non-AdV pneumonia patients (mean 3.8 vs. 2.6 days, P < 0.001).
Characteristics and outcomes of 69 patients with AdV-55 pneumonia
Because there are only limited data on the characteristics of AdV pneumonia caused by serotype AdV-55 and there has been concern about the highly virulent serotypes (13), we described the characteristics and outcomes of the 69 patients with AdV-55 pneumonia ( Table 5 ), given that most of the isolates typed in our study were AdV-55. Of the 69 patients with AdV-55 pneumonia, 42 (60.9%) required oxygen, 8 (11.6%) needed a vasopressor, and 13 (18.8%) had pneumonia severity index ≥ class III. Also, leukopenia (n = 24, 34.8%) and thrombocytopenia (n = 39, 56.5%) were commonly observed. Five (7.2%) patients had co-infections with other respiratory viruses such as rhinovirus or enterovirus, and bacterial agents were identified in 30.4% of patients. Most patients (40/63, 63.5%) had consolidation with ground-glass opacity patterns on chest CT. More than a third of patients (n = 24, 34.8%) had respiratory failure, and one patient with AdV-55 pneumonia died of respiratory failure and massive hemorrhagic infarction.
DISCUSSION
One of the most noticeable findings in our study was that AdV pneumonia in previously healthy young adults had distinctive clinico-laboratory and radiological findings compared with non- Data are shown as mean ± standard deviation or number (%). AdV = adenovirus, CT = computed tomography, ECMO = extracorporeal membrane oxygenation, IVIG = intravenous immunoglobulin, NA = not applicable.
AdV pneumonia patients. In our study conducted in Korean military personnel, AdV pneumonia patients were more likely to have consolidation with ground-glass opacity in lobar distribution, not uncommonly accompanied by cytopenic blood profiles including leukopenia or thrombocytopenia, and systemic symptoms including myalgia or diarrhea. Studies on the clinical features of AdV pneumonia in non-immunocompromised patients that support our data have consistently been reported (7, 12, 19, 20) . For example, in a study that reported 6 cases of severe AdV pneumonia that occurred in a psychiatric care facility, most patients (5/6, 83.3%) had dense lower lobe consolidation on chest radiographs and all patients had a transient fall in WBC and platelet counts in the course of the disease (7). In another study, which compared the characteristics between AdV-55 and other AdV serotypes among 48 AdV pneumonia patients, approximately half of them had consolidation on chest radiographs and only 12.5% had elevated WBC counts (12) . In an additional study, which evaluated 115 CT findings of 93 viral and 23 bacterial pneumonia cases, AdV tended to have characteristic imaging results, most of which (7/10, 70%) showed multifocal consolidation or ground-glass opacity (21) . However, there is still a lack of data on the detailed clinico-radiological features of AdV pneumonia, especially in non-immunocompromised patients; thus in this context, our data may have clinical significance because it provides suggestive findings of AdV pneumonia, which could help physicians to determine further diagnostic or treatment strategies at the time of presentation of pneumonia.
In recent years, concerns regarding the highly virulent serotype have increased and studies have reported fatal cases caused by specific AdV serotypes such as AdV-3, -7, -11, -14, and -55 (10, 11, 13, 14, 16, 17, 19) , especially in relatively vulnerable populations such as military personnel. Among Korean military personnel, 6 patients with severe AdV pneumonia caused by AdV-55 were first identified between 2012 and 2014 (16); other severe pneumonia cases associated with AdV-55 have been identified. Interestingly, during the same period, 5 fatal cases of AdV pneumonia caused by AdV-55-with 80% mortality rate-were reported in China (13) , which also highlights the emerging highly virulent AdV pathogens. An outbreak of AdV respiratory infection including severe pneumonia was also reported in Chinese military trainees and efforts have been made to identify the immunological profiles of patients with AdV-55 pneumonia (9) , which may partly help to identify those more vulnerable to developing severe disease and to develop a treatment strategy. In our study, because approximately one third of the 69 patients with pneumonia caused by AdV-55 had respiratory failure (one of whom died), one might consider AdV-55 as a virulent pathogen. However, given that we could not compare AdV-55 with other AdV serotypes and most of the isolates typed in outpatients without pneumonia during the study period were also AdV-55, our data imply that AdV-55 is not always associated with severe respiratory disease, although it can cause fatal pneumonia, even in non-immunocompromised patients. Regarding these points, no accurate data exist and further well-designed studies https://doi.org/10.3346/jkms.2017.32.2.287 of the serotype and host vulnerabilities are required. In our study, bacterial co-infections in AdV pneumonia patients were identified in 28.5% (47/165) of patients, and S. pneumoniae, H. influenzae, and M. pneumoniae were commonly identified. It is generally known that bacterial co-infection is associated with up to 40% of viral respiratory infections, and is an important contributor to morbidity in pneumonia (22) (23) (24) . Regarding bacterial co-infections associated with AdV infection, one recent study has described elevated serum procalcitonin levels ( > 0.5 ng/mL), suggesting the possibility of bacterial coinfection in 4 of 12 AdV pneumonia patients (12) . However, there are no accurate data on the incidence, clinical implications, or pathogenesis of bacterial co-infections associated with AdV respiratory infections. In this context, our data may provide significant information on the incidence and bacterial types, but further studies are needed.
Our study had several limitations. First, because our study was conducted at a military hospital, our cohort was not representative of the general population in terms of age, gender, or underlying condition. Thus, our data cannot be applied to mild or severely immunocompromised patients. Second, not all of the isolated AdV samples underwent serologic analysis; thus, inflammatory responses to different AdV serotypes should be evaluated. Third, because of the retrospective design, the possible effects of unidentified bacterial or viral co-infections on the clinical characteristics of pneumonia cannot be excluded. Lastly, there is a possibility that some AdV pneumonia patients might not have been included in our characteristics analysis because not all CAP patients underwent PCR tests for respiratory viruses and a relatively large numbers of CAP patients (n = 173, Fig. 1 ) was excluded from the analysis.
In conclusion, our data showed that AdV pneumonia in nonimmunocompromised patients had distinct characteristics and most of the isolates typed in our study were AdV-55, which suggested that AdV-55 is an important pathogen for pneumonia. However, further surveillance is needed because limited data exist.
